bioMerieux (OTCMKTS:BMXMF – Get Free Report) gapped up prior to trading on Thursday. The stock had previously closed at $95.00, but opened at $99.55. bioMerieux shares last traded at $99.55, with a volume of 32 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on BMXMF shares. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a report on Monday, September 28th. Morgan Stanley restated an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Five research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce”.
Read Our Latest Stock Analysis on bioMerieux
bioMerieux Stock Down 1.0%
The company’s fifty day moving average is $87.26 and its two-hundred day moving average is $86.03.
About bioMerieux
bioMérieux is a France-based company specializing in in vitro diagnostics. It develops and manufactures diagnostic systems, reagents, software and services used to detect disease, identify infectious organisms and support treatment decisions. Its offerings serve hospitals, clinical laboratories and other healthcare providers, with a particular focus on infectious diseases, antimicrobial resistance and syndromic testing.
The company also provides industrial microbiology solutions for applications such as food safety, pharmaceutical manufacturing and quality control.
See Also
- Five stocks we like better than bioMerieux
- Flywire’s Rapid Growth Faces a Q3 Test—Is Its Stock Already Too Expensive?
- Cologuard Is Working—So Why Isn’t Abbott Stock?
- Micron’s Taiwan Strike: A High-Stakes Fight Over AI Profits
- Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.
